Dactolisib (BEZ235, NVP-BEZ235)

目录号：S1009

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。在 3T3^TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Phase 2。

规格

价格

库存

购买数量

50mg	RMB 895.88	现货
100mg	RMB 1414.41	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献180篇：

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )
Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )
Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )
Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )
Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )
Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )
Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

靶点

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	点击更多
4 nM	5 nM	6 nM	7 nM	21 nM	点击更多

体外研究

BEZ235显著降低mTOR活化的激酶p70S6K的磷酸化水平。BEZ235导致S235/S236P-RPS6水平减少，IC50为6.5 nM。BEZ235抗mTOR的活性使用生化mTOR K-LISA试验测定，IC50为20.7 nM。BEZ235对其β旁系同源物的活性稍弱，IC50为75 nM。在人肿瘤细胞中，PI3K/Akt/mTOR通路经常被组成性活化。BEZ235阻断PI3K和mTOR激酶活性，通过结合于这些酶的ATP结合槽发挥作用。用逐渐增加浓度BEZ235处理PTEN-null细胞系PC3M和U87MG时，导致细胞增殖剂量依赖性减少，平均GI50为10-12 nM。^[1] BEZ235是一种mTORC1/2催化抑制剂。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MoHsRY51cW2rY4LvZolidCCDc4PhfS=>		M2jHVVE5KGh?	MUDEUXNQ	MoflRY51cXS{eYDhco9{d22jbDDhZ5Rqfmm2eTD3bZRpKEWFNUCgc4YhOC5yMEK1JO69VQ>?	M1rMTVI1QDB3OUS2
MCF7	NF:xe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIP0d3YxNjBzLUGwNEDPxE1?	MWG0PEBp	NU[3NpZmTE2VTx?=	Mle2TWM2OD1yLkezJO69VQ>?	NUfoU3dGOjN6N{G5NFQ>
HCT116	NHrJWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\XNE4xOS1zMECg{txO	NV;xUnJvPDhiaB?=	M{fwPWROW09?	NY\1OWhPUUN3ME2xMlE3KM7:TR?=	Ml;CNlM5PzF7MES=
U87MG	NGjEVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVywMlAyNTFyMDFOwG0>	MXy0PEBp	MYLEUXNQ	NWCwPJViUUN3ME2xMlMzKM7:TR?=	MVSyN\|g4OTlyNB?=
HBC4	M1XhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P6WVAvODFvMUCwJO69VQ>?	NWmwVmEyPDhiaB?=		NWXwenR4VG:pIFfJOVA:NThwNkGgUS=>	NF3nR2gzOjN\|NkK0Oi=>
BSY1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXewMlAyNTFyMDFOwG0>	NIjrclI1QCCq		NHzjNW1Nd2diR1m1NF0uQC52ODDN	M1zhNlIzOzN4MkS2
HBC5	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLhfYIxNjBzLUGwNEDPxE1?	NWHnOlZRPDhiaB?=		NYXUbYt7VG:pIFfJOVA:NTdwOEegUS=>	M2fkR\|IzOzN4MkS2
MCF7	NHXZfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPsfmRvOC5yMT2xNFAh\|ryP	NFHBd5Q1QCCq		NVzLO\|FqVG:pIFfJOVA:NThwMU[gUS=>	NXTw[nQ4OjJ\|M{[yOFY>
MDA-MB-231	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXywMlAyNTFyMDFOwG0>	MnzNOFghcA>?		NVzDflR[VG:pIFfJOVA:NThwMEmgUS=>	MUWyNlM{PjJ2Nh?=
U251	NF:zfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjMfYoxNjBzLUGwNEDPxE1?	M3LiVlQ5KGh?		NHLRRYRNd2diR1m1NF0uPy54NjDN	MVGyNlM{PjJ2Nh?=
SF268	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTlNE4xOS1zMECg{txO	M332WFQ5KGh?		NHPpN3FNd2diR1m1NF0uPy57MjDN	M3;aXFIzOzN4MkS2
SF295	NFmySZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSwMlAyNTFyMDFOwG0>	NHj1fpc1QCCq		NFPOOnJNd2diR1m1NF0uQC5\|MTDN	NVPoRm9ZOjJ\|M{[yOFY>
SF539	NInyT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\3RVAvODFvMUCwJO69VQ>?	M1HPblQ5KGh?		MknEUI9oKEeLNUC9MVgvPTliTR?=	M3jiVFIzOzN4MkS2
SNB75	NXTzR3pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX2zN3AyOC5yMT2xNFAh\|ryP	NV;6SmpoPDhiaB?=		M1;pbWxw\yCJSUWwQU05NjV6IF2=	Mnq1NlI{OzZ{NE[=
SNB78	M3PpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPQXpoxOC5yMT2xNFAh\|ryP	MmLJOFghcA>?		MXfMc4chT0l3ME2tPE43PSCP	NUjhNINLOjJ\|M{[yOFY>
HCC2998	M2LOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;0VYVJOC5yMT2xNFAh\|ryP	M{DDd\|Q5KGh?		MlqzUI9oKEeLNUC9MVgvODViTR?=	MmfiNlI{OzZ{NE[=
KM12	NHzUelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLzfHYxNjBzLUGwNEDPxE1?	NIHD[mY1QCCq		NHHiUGRNd2diR1m1NF0uPy53NDDN	M1fGOVIzOzN4MkS2
HT-29	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPkPGgxNjBzLUGwNEDPxE1?	NXLiPIg5PDhiaB?=		M1ftN2xw\yCJSUWwQU04Njd3IF2=	MWOyNlM{PjJ2Nh?=
HCT15	MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSwMlAyNTFyMDFOwG0>	NGHKRlQ1QCCq		NI[4fVBNd2diR1m1NF0uQC5yMzDN	MkHrNlI{OzZ{NE[=
HCT116	Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLiTGgxNjBzLUGwNEDPxE1?	Mo\vOFghcA>?		MV;Mc4chT0l3ME2tO{43OSCP	M{W4ZlIzOzN4MkS2
NCI-H23	NXLrXmI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TVOVAvODFvMUCwJO69VQ>?	NWjJeZNPPDhiaB?=		MXLMc4chT0l3ME2tO{43PCCP	NEXiWmUzOjN\|NkK0Oi=>
NCI-H226	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonpNE4xOS1zMECg{txO	M2XKd\|Q5KGh?		MXHMc4chT0l3ME2tPE41PCCP	NEPYRlgzOjN\|NkK0Oi=>
NCI-H522	MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYGwMlAyNTFyMDFOwG0>	NXHoe21JPDhiaB?=		NIe0VIRNd2diR1m1NF0uQC52NTDN	NHP3UZYzOjN\|NkK0Oi=>
NCI-H438	M3LLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHJ[ocxNjBzLUGwNEDPxE1?	MWe0PEBp		NXnIU2lyVG:pIFfJOVA:NThwMUGgUS=>	NFHqdJMzOjN\|NkK0Oi=>
A549	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrRSWoxNjBzLUGwNEDPxE1?	MYW0PEBp		NYLh[FZqVG:pIFfJOVA:NThwMEegUS=>	NHfvc4IzOjN\|NkK0Oi=>
DMS273	NVXXWotwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrGeGExNjBzLUGwNEDPxE1?	MXi0PEBp		M1O3S2xw\yCJSUWwQU04NjhyIF2=	Mn;lNlI{OzZ{NE[=
DMS114	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP1bWcxNjBzLUGwNEDPxE1?	MXm0PEBp		NY\RTVRGVG:pIFfJOVA:NThwM{mgUS=>	M2XxSFIzOzN4MkS2
LOXIMVI	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLLNE4xOS1zMECg{txO	Mor0OFghcA>?		M2P5XWxw\yCJSUWwQU05NjZ4IF2=	MlXMNlI{OzZ{NE[=
OVCAR3	M4LoZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPoSJFSOC5yMT2xNFAh\|ryP	NG\5b\|c1QCCq		NVe1RmNWVG:pIFfJOVA:NThwMUegUS=>	M3uxNlIzOzN4MkS2
OVCAR4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1:5RVAvODFvMUCwJO69VQ>?	MWm0PEBp		M4XobWxw\yCJSUWwQU05NjV6IF2=	MYGyNlM{PjJ2Nh?=
OVCAR5	M3\jOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f1bFAvODFvMUCwJO69VQ>?	MUC0PEBp		MorXUI9oKEeLNUC9MVcvPTdiTR?=	MUKyNlM{PjJ2Nh?=
OVCAR8	NX7SOmZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV2wMlAyNTFyMDFOwG0>	NEPQUIM1QCCq		NXzrU5ZCVG:pIFfJOVA:NTdwOESgUS=>	NXHsSmtCOjJ\|M{[yOFY>
SKOV3	NUXCcmFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjYSGpCOC5yMT2xNFAh\|ryP	M{DJTVQ5KGh?		M3r6SWxw\yCJSUWwQU05NjRzIF2=	NWPVT5FHOjJ\|M{[yOFY>
RXF631L	M4HBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXGNE4xOS1zMECg{txO	M2WxVFQ5KGh?		M2\qW2xw\yCJSUWwQU05NjJzIF2=	MnfwNlI{OzZ{NE[=
ACHN	M{j2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzQNE4xOS1zMECg{txO	NXHySVJzPDhiaB?=		MnqyUI9oKEeLNUC9MVcvQTViTR?=	MlSyNlI{OzZ{NE[=
St-4	NFjq[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\QfIIxNjBzLUGwNEDPxE1?	NH;6WHk1QCCq		M1vJRWxw\yCJSUWwQU04NjR5IF2=	Ml;jNlI{OzZ{NE[=
MKN1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXywMlAyNTFyMDFOwG0>	NFrINHY1QCCq		M2n0d2xw\yCJSUWwQU05NjRzIF2=	NX\He\|I4OjJ\|M{[yOFY>
MKN7	NYixc2JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn[zNE4xOS1zMECg{txO	MoG5OFghcA>?		MonCUI9oKEeLNUC9MVcvPjhiTR?=	M{TFWVIzOzN4MkS2
MKN28	Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mon6NE4xOS1zMECg{txO	NX7DZZNNPDhiaB?=		NF7qe3pNd2diR1m1NF0uPy5yNzDN	NI\1RYQzOjN\|NkK0Oi=>
MKN45	M{XBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\tdXVGOC5yMT2xNFAh\|ryP	Mn;mOFghcA>?		Ml;1UI9oKEeLNUC9MVgvOzRiTR?=	MUSyNlM{PjJ2Nh?=
MKN74	NFnWWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fNPVAvODFvMUCwJO69VQ>?	NEnETpM1QCCq		M2DJb2xw\yCJSUWwQU04NjR{IF2=	NFexOlgzOjN\|NkK0Oi=>
DU145	NXrVT3hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLhemJJOC5yMT2xNFAh\|ryP	M3TBc\|Q5KGh?		M1T4VGxw\yCJSUWwQU05NjF4IF2=	NHrkXJMzOjN\|NkK0Oi=>
PC3	NXPYVW5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzJZo4zOC5yMT2xNFAh\|ryP	M1[zZlQ5KGh?		NWXTPItPVG:pIFfJOVA:NThwNk[gUS=>	M1\JZ\|IzOzN4MkS2
Trypanosoma brucei brucei	NXvvOmRlTnWwY4Tpc44hSXO\|YYm=	MV[yNFAhdk1?	NGns[lgyOiCq	MYrEUXNQ	NXHCfW5LTGWlcnXhd4UhcW5icHjvd5Bpd3SrZInsJIlvd3OrdH;sJJBpd3OyaHH0[UBt\X[nbB?=	NU\3bnFYOjR6MEW5OFY>
Trypanosoma brucei brucei	M1z6PGZ2dmO2aX;uJGF{e2G7		NEXNSnIyQCCq	M{O1ZmROW09?	Mlm0TY5pcWKrdHnvckBw\iC{ZXPldJRwei2vZXTpZZRm\CCnbnTvZ5l1d3OrczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC2cnHud4ZmenKrbjD1dJRic2V?	NFL1[5UzPDhyNUm0Oi=>
Trypanosoma brucei brucei	MofoSpVv[3Srb36gRZN{[Xl?	M2XRc\|IxOCCwTR?=	MoPBNVIhcA>?	M4T1[WROW09?	M3LlZWVn\mWldDDvckB{eGirbnfvcZlt\WmwIHzleoVt	NGnFclEzPDhyNUm0Oi=>
Trypanosoma brucei brucei	Ml;USpVv[3Srb36gRZN{[Xl?	NIHqNIkzODBibl2=	NHzidooyOiCq	MUDEUXNQ	MX7F[oZm[3Rib36gdIhwe3CqYYTp[Jlt[2ixbHnu[UBt\X[nbB?=	MoDjNlQ5ODV7NE[=
UM-UC-3	NILoe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoOzTWM2OD1\|MUWgdG0>	NIj5VXBUSU6JRWK=
SBC-1	MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWezbJBjUUN3ME23OFIheE1?	NG\pV\|hUSU6JRWK=
MKN1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHwTWM2OD1{Lkigcm0>	MXfTRW5ITVJ?
NCI-H720	NGKycJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrYTWM2OD1\|LkW3JI5O	M2\UOHNCVkeHUh?=
BFTC-909	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7yenlHUUN3ME2zMlcyKG6P	MnrNV2FPT0WU
BPH-1	M1nyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjyPG82UUN3ME20Mlc3KG6P	M1fGS3NCVkeHUh?=
PC-3	NXnO[GZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml60TWM2OD13LkC5JI5O	MmjwV2FPT0WU
AN3-CA	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\OOmlEPTB;NT61OkBvVQ>?	NGf6S2pUSU6JRWK=
HN	NYrybVlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LYTWlEPTB;NT65OkBvVQ>?	MlrUV2FPT0WU
HCC2218	NInaUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\qbZlKSzVyPU[uOlEhdk1?	NFP5dnNUSU6JRWK=
KP-4	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M364[GlEPTB;NzDuUS=>	M1S2SHNCVkeHUh?=
LU-139	NVvQRod7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjQTWM2OD15Lke3JI5O	NFvGV3ZUSU6JRWK=
ETK-1	M3jQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7ZOFdNUUN3ME23Mlg5KG6P	MkjhV2FPT0WU
Ramos-2G6-4C10	NIf0c2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2n5TWlEPTB;OD60PUBvVQ>?	MUPTRW5ITVJ?
MHH-PREB-1	M2[2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfKTWM2OD17LkGyJI5O	M{nDcXNCVkeHUh?=
DU-4475	NWWzPIx7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXibG1KSzVyPUmuOFQhdk1?	NHLBUHFUSU6JRWK=
NCI-H1666	NV7JOndET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYD1dIg6UUN3ME25MlcyKG6P	M3fyU3NCVkeHUh?=
CAMA-1	M2rCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nTRmlEPTB;OT64JI5O	MoTaV2FPT0WU
TYK-nu	NGfrdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrMTWM2OD17Lkm0JI5O	NWjvdXg3W0GQR1XS
MFE-280	M4rTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTlwOUmgcm0>	NEPGbWdUSU6JRWK=
A549	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHi2SldKSzVyPUGwMlE1KG6P	Ml[3V2FPT0WU
769-P	NWHGcHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfJNYtKSzVyPUGwMlQ1KG6P	NHrlXVNUSU6JRWK=
L-363	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnu5TWM2OD1zMD62PUBvVQ>?	Mof6V2FPT0WU
ES8	M17OUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLwTWM2OD1zMD65JI5O	M3;vT3NCVkeHUh?=
PA-1	NFG4NnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfJTWM2OD1zMT64NkBvVQ>?	NEW2eotUSU6JRWK=
Mewo	NFzPeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3Xe\|VKSzVyPUGxMlk6KG6P	MWPTRW5ITVJ?
HSC-3	M3nOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTF{LkKxJI5O	NGDJRZdUSU6JRWK=
H4	M2\xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTF{Lk[3JI5O	MVPTRW5ITVJ?
BB65-RCC	NXXkWlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTF{LkeyJI5O	M2qwTHNCVkeHUh?=
NCI-H1793	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLDOHhKSzVyPUGyMlgzKG6P	NUm3c2F7W0GQR1XS
KARPAS-45	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jaVGlEPTB;MUOuOVEhdk1?	NWn3d3h6W0GQR1XS
GCT	M3S1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjLTnpKSzVyPUGzMlY5KG6P	Mn3DV2FPT0WU
EoL-1	M{DkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3M[VIzUUN3ME2xN{46OyCwTR?=	NWnIS4xMW0GQR1XS
LB2241-RCC	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPkTWM2OD1zND6wNUBvVQ>?	MmLVV2FPT0WU
ES5	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnWWIJKSzVyPUG0Mlc1KG6P	M3nsfXNCVkeHUh?=
LOXIMVI	M1K4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\tTWM2OD1zND65PUBvVQ>?	Mk\IV2FPT0WU
COR-L105	Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLGOHFKSzVyPUG1MlA1KG6P	M2jIXHNCVkeHUh?=
P12-ICHIKAWA	NUL0UJRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX75PZR{UUN3ME2xOU4yKG6P	M1TzbHNCVkeHUh?=
CHL-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTF3LkS1JI5O	MWjTRW5ITVJ?
VMRC-RCZ	MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXtZ5hKSzVyPUG1MlY{KG6P	MXTTRW5ITVJ?
HH	NI\KfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYK2bGpxUUN3ME2xOU44KG6P	M{LoSnNCVkeHUh?=
NUGC-3	NHO2TG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTF4LkO0JI5O	MmfZV2FPT0WU
EGI-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fZWGlEPTB;MU[uOFMhdk1?	NFj1dmxUSU6JRWK=
OS-RC-2	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXRTWM2OD1zNj60O{BvVQ>?	M3zDNXNCVkeHUh?=
MOLT-16	NWnuO3Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoX1TWM2OD1zNz6xOUBvVQ>?	NUfONXVoW0GQR1XS
NCI-H209	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTwVJlKSzVyPUG3MlI6KG6P	Mn3NV2FPT0WU
697	NYD6d3VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTF5LkSzJI5O	NUfE[5ZwW0GQR1XS
D-56MG	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1f5TmlEPTB;MUeuOlkhdk1?	NWPSW\|ZWW0GQR1XS
VA-ES-BJ	NX:5U49xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTF5LkizJI5O	MkHIV2FPT0WU
EW-16	NEDQN\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1P4e2lEPTB;MUiuNFQhdk1?	MmezV2FPT0WU
HGC-27	NH3yfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTHV29TUUN3ME2xPE4xPiCwTR?=	MkXLV2FPT0WU
ES7	NITZfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\IOnZFUUN3ME2xPE4xQSCwTR?=	MVvTRW5ITVJ?
HuH-7	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfzXnVKSzVyPUG4MlQhdk1?	M2GwWHNCVkeHUh?=
BCPAP	NWTGUnlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mle1TWM2OD1zOD62OUBvVQ>?	NX\tbWNDW0GQR1XS
SW1710	M3TlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHMe2I3UUN3ME2xPE44OiCwTR?=	NILiVYRUSU6JRWK=
IST-MEL1	NWWwZ3VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjYTWM2OD1zOD63O{BvVQ>?	NYrsXWZGW0GQR1XS
SF295	MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37JbWlEPTB;MUiuPVMhdk1?	MljXV2FPT0WU
RPMI-7951	NGS0PYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnDcoRKSzVyPUG5MlI5KG6P	M3e1[XNCVkeHUh?=
SF126	NXP2[XJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfnXWJKSzVyPUG5MlQyKG6P	M1u1fHNCVkeHUh?=
GAMG	NYnZVlZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDUU\|RKSzVyPUG5MlQ5KG6P	M2jxe3NCVkeHUh?=
KNS-81-FD	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTF7LkW0JI5O	MYHTRW5ITVJ?
RT-112	NFvhZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTJTo9oUUN3ME2xPU43PiCwTR?=	NE\mSmVUSU6JRWK=
DEL	NH\v[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInkUHdKSzVyPUKwMlQ6KG6P	M373O3NCVkeHUh?=
CGTH-W-1	NHrrPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTJyLk[zJI5O	MlnYV2FPT0WU
HOS	M1fje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NISwO\|BKSzVyPUKxMlA3KG6P	NYXrdWFDW0GQR1XS
ES4	MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJzLkC4JI5O	MojEV2FPT0WU
RXF393	NH;DN\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoS5TWM2OD1{MT60OUBvVQ>?	NGPWTY9USU6JRWK=
NCI-H2030	Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;6TWM2OD1{MT61NkBvVQ>?	MmruV2FPT0WU
YH-13	M2fOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjX[4hKSzVyPUKxMlg5KG6P	MUnTRW5ITVJ?
HT-1080	MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXKVJJDUUN3ME2yNU46OyCwTR?=	MlvxV2FPT0WU
NCI-SNU-1	NGjhU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn75TWM2OD1{MT65OUBvVQ>?	NHfxSGVUSU6JRWK=
G-402	M1v1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTqbGZKSzVyPUKyMlE3KG6P	NUHG[FR7W0GQR1XS
786-0	NHHJbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTqbJNnUUN3ME2yNk4zQSCwTR?=	MWfTRW5ITVJ?
ME-180	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TUb2lEPTB;MkKuOFMhdk1?	Ml3hV2FPT0WU
NB69	NGXvVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTJ{LkWzJI5O	MW\TRW5ITVJ?
J-RT3-T3-5	M4PCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWf0NYRIUUN3ME2yNk46PiCwTR?=	NX;1UXRrW0GQR1XS
TGBC1TKB	M3q0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEi4T4lKSzVyPUKzMlA2KG6P	M2[3WnNCVkeHUh?=
SW780	Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfO[4xOUUN3ME2yN{4yOyCwTR?=	NUDDR\|dxW0GQR1XS
MG-63	NXH5dotoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJ\|LkS1JI5O	MV7TRW5ITVJ?
BV-173	NUPxT2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJ\|Lki3JI5O	NX7VfFBPW0GQR1XS
CAL-51	NFnINWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTXXnVmUUN3ME2yN{45QSCwTR?=	Mn63V2FPT0WU
A375	Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnOTWM2OD1{Mz65N{BvVQ>?	Ml;EV2FPT0WU
MEL-HO	NUjt[\|ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfhTZdKSzVyPUK0MlA1KG6P	NFzCVYpUSU6JRWK=
EFO-27	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnuxTWM2OD1{ND6zN{BvVQ>?	MoLGV2FPT0WU
Hs-578-T	NUj5flBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPSTWM2OD1{ND61PEBvVQ>?	MVPTRW5ITVJ?
NBsusSR	NGLzeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HRdGlEPTB;MkSuOkBvVQ>?	MYjTRW5ITVJ?
CTB-1	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrGTnBKSzVyPUK0MlY4KG6P	MWXTRW5ITVJ?
FTC-133	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoS0TWM2OD1{NT6xJI5O	MY\TRW5ITVJ?
MOLT-4	NVnBV4h3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnyTWM2OD1{NT6xNkBvVQ>?	Moj0V2FPT0WU
HO-1-N-1	NF3tPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fhc2lEPTB;MkWuNVUhdk1?	MkPaV2FPT0WU
ES3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\wSJZKSzVyPUK1MlIzKG6P	MUTTRW5ITVJ?
TI-73	NHuyZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTJ3LkK4JI5O	NEjxOWFUSU6JRWK=
MPP-89	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1G5fmlEPTB;MkWuN\|Ihdk1?	MX7TRW5ITVJ?
KYSE-150	M{CyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\DXpdKSzVyPUK1Mlg6KG6P	MkDkV2FPT0WU
LXF-289	M{G3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPhcVhKSzVyPUK2MlA1KG6P	MUTTRW5ITVJ?
SK-LU-1	NUnRTmw6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjqTWM2OD1{Nj6xO{BvVQ>?	MV3TRW5ITVJ?
HOP-92	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3[xWWlEPTB;Mk[uOFghdk1?	M4PNV3NCVkeHUh?=
HuO9	NIrkRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTJ4Lke2JI5O	MWLTRW5ITVJ?
SW962	NXHmS3ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3P2fmlEPTB;Mk[uO\|Yhdk1?	NUD3UGJPW0GQR1XS
RS4-11	NInIZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnyVZhKSzVyPUK2MlkyKG6P	MYjTRW5ITVJ?
NCI-H292	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXaXpRKSzVyPUK3JI5O	MoXiV2FPT0WU
DB	NXnYU\|JYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvac2hRUUN3ME2yO{4{PiCwTR?=	NIPOe21USU6JRWK=
SW1088	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7oSm5KSzVyPUK4MlI6KG6P	MoWzV2FPT0WU
A204	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHpXGJKSzVyPUK4MlQ4KG6P	NXPUbJFDW0GQR1XS
A3-KAW	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLxTWM2OD1{OD62OEBvVQ>?	M4nRW3NCVkeHUh?=
MV-4-11	Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWL2UZIxUUN3ME2yPE44KG6P	NH7Yfo9USU6JRWK=
ES1	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkC3TWM2OD1{OD64OEBvVQ>?	MojYV2FPT0WU
ONS-76	NEDIdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moj1TWM2OD1{OT6wOUBvVQ>?	MXvTRW5ITVJ?
D-263MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fJN2lEPTB;MkmuN\|Uhdk1?	NFjC[4NUSU6JRWK=
U-2-OS	NUW0cnQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVixRZhYUUN3ME2yPU42KG6P	Mmn6V2FPT0WU
T98G	M3jU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrJTWM2OD1{OT64PEBvVQ>?	NGjRPXpUSU6JRWK=
GI-ME-N	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fyUWlEPTB;MkmuPVEhdk1?	MnLIV2FPT0WU
BHT-101	MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfHSIRxUUN3ME2zNE4xPSCwTR?=	NID0Z3lUSU6JRWK=
NOS-1	M4fuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTNyLkGyJI5O	M{mzenNCVkeHUh?=
AsPC-1	NH71NWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvSTWM2OD1\|MD6yJI5O	NWTDXllsW0GQR1XS
QIMR-WIL	NH;YdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC4W49KSzVyPUOwMlYhdk1?	MUPTRW5ITVJ?
JVM-3	MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjyfoRmUUN3ME2zNE45OyCwTR?=	NWLQPZNFW0GQR1XS
KU-19-19	MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXF[2ZKSzVyPUOxMlE{KG6P	M4DTR3NCVkeHUh?=
OVCAR-8	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHi0T2xKSzVyPUOxMlI3KG6P	NY\VfWJOW0GQR1XS
BEN	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;6bWlEPTB;M{GuOlMhdk1?	NEL5PXVUSU6JRWK=
BE-13	M3nzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjIN2JKSzVyPUOxMlgzKG6P	NEW1[pZUSU6JRWK=
EW-18	MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnHTWM2OD1\|MT64OkBvVQ>?	M{[5S3NCVkeHUh?=
ECC10	M{TRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTNzLkm1JI5O	NHX0dIVUSU6JRWK=
CTV-1	MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\KSGlEPTB;M{KuPFIhdk1?	MnvEV2FPT0WU
COLO-800	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH[0d5VKSzVyPUOyMlkzKG6P	NYnVWYVPW0GQR1XS
A2058	NWj3c2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXKTWM2OD1\|Mz6yOUBvVQ>?	NY\me5hRW0GQR1XS
VM-CUB-1	M{PTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nrbGlEPTB;M{OuOFMhdk1?	NELUepBUSU6JRWK=
Ca9-22	M3\lZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTN\|LkW1JI5O	MkKzV2FPT0WU
COLO-684	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XU[WlEPTB;M{OuOVghdk1?	MX7TRW5ITVJ?
RPMI-8226	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDrbZBKSzVyPUOzMlgzKG6P	MUPTRW5ITVJ?
SK-NEP-1	M2Dafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\aeIdKSzVyPUO0MlE2KG6P	MYnTRW5ITVJ?
Becker	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTPNHNkUUN3ME2zOE4zOSCwTR?=	NWG1N3dSW0GQR1XS
NCI-H28	M3vtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvQTWM2OD1\|ND60OEBvVQ>?	MVrTRW5ITVJ?
CAL-120	NU\3THVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DsUmlEPTB;M{SuO\|Ihdk1?	M3z5S3NCVkeHUh?=
MDA-MB-157	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzHXIhKSzVyPUO1MlQyKG6P	NIHHdVBUSU6JRWK=
OVCAR-5	NF6wTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rZUGlEPTB;M{WuOFchdk1?	NG\BNplUSU6JRWK=
LAMA-84	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPnTWM2OD1\|NT64O{BvVQ>?	MmHtV2FPT0WU
CAKI-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17NOGlEPTB;M{[uOFMhdk1?	Mn;JV2FPT0WU
Daoy	NHfLb\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE[0TG1KSzVyPUO2Mlchdk1?	MVXTRW5ITVJ?
CAL-62	NYTEeXJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYn0OYtjUUN3ME2zOk45PiCwTR?=	M4nORnNCVkeHUh?=
8-MG-BA	NFzkWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2D5UmlEPTB;M{euNlUhdk1?	NFPYSoNUSU6JRWK=
8505C	M3q2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\3bVlKSzVyPUO3MlUyKG6P	NI\VUXVUSU6JRWK=
LNCaP-Clone-FGC	NI[1dlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG[yXnFKSzVyPUO3MlU6KG6P	NWflc49xW0GQR1XS
CAL-39	NWHGV4dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DsR2lEPTB;M{euPUBvVQ>?	M3L6THNCVkeHUh?=
MN-60	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLM[nI1UUN3ME2zO{46PiCwTR?=	NFGzTVZUSU6JRWK=
RKO	MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTN6LkOzJI5O	NXX1cG9lW0GQR1XS
U251	MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF21Wm5KSzVyPUO4MlQ{KG6P	MnvUV2FPT0WU
SJSA-1	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\JZ2lEPTB;M{iuOVQhdk1?	MUHTRW5ITVJ?
CAL-12T	Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXZXppKSzVyPUO4MlYhdk1?	MVXTRW5ITVJ?
HCC1419	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTN6LkexJI5O	NV3tWJVIW0GQR1XS
CO-314	M3rZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHFTWM2OD1\|OD63OEBvVQ>?	NIrFZWdUSU6JRWK=
LB1047-RCC	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXtdJpKSzVyPUO4MlgyKG6P	MXfTRW5ITVJ?
A101D	MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:0d5ZKSzVyPUO4Mlk4KG6P	Mnz1V2FPT0WU
MDA-MB-175-VII	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vaXGlEPTB;M{muOVEhdk1?	MVjTRW5ITVJ?
MZ2-MEL	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\1TWM2OD1\|OT62OkBvVQ>?	MVHTRW5ITVJ?
NB5	NWjjeXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TSOGlEPTB;NECuOlQhdk1?	NEHS[pVUSU6JRWK=
G-401	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnDTWM2OD12MD64NkBvVQ>?	NX\kUWpmW0GQR1XS
HT	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWryem1yUUN3ME20NU4xOiCwTR?=	NYfBSZRZW0GQR1XS
8305C	NWfZVWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTRzLki3JI5O	NVLsUFBCW0GQR1XS
BHY	MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTR{LkeyJI5O	NFzXPIRUSU6JRWK=
NTERA-S-cl-D1	NETZcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTR\|IH7N	M4H2UnNCVkeHUh?=
T-24	M3nk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTR\|LkizJI5O	M2Xj[XNCVkeHUh?=
EPLC-272H	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXQTWM2OD12ND6zPUBvVQ>?	MUPTRW5ITVJ?
PSN1	NXHPOGE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHZeFlrUUN3ME20OE41KG6P	MXHTRW5ITVJ?
NCI-H2452	M1rCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHyzbJpKSzVyPUS0MlU5KG6P	MoHOV2FPT0WU
KS-1	M4fFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULBc2dNUUN3ME20OE43PiCwTR?=	MonUV2FPT0WU
HD-MY-Z	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTR2LkmyJI5O	NFrjRXBUSU6JRWK=
KNS-62	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjmXGdIUUN3ME20OU4{QCCwTR?=	NHTSdFBUSU6JRWK=
NOMO-1	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWG0RWN7UUN3ME20OU45PyCwTR?=	NFrMTVdUSU6JRWK=
SK-HEP-1	NHfseVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTR4LkC0JI5O	MoHZV2FPT0WU
IGR-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DSN2lEPTB;NE[uNVMhdk1?	MoHZV2FPT0WU
KYSE-180	M2DJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fXZmlEPTB;NE[uNVchdk1?	NHTER29USU6JRWK=
EW-22	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;LTWM2OD12Nj6yJI5O	M2\5bnNCVkeHUh?=
NCI-H1355	NYXhVFI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;HemlEPTB;NE[uN\|Qhdk1?	MYTTRW5ITVJ?
DOHH-2	NFH0OYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LTU2lEPTB;NE[uN\|chdk1?	MVTTRW5ITVJ?
A4-Fuk	Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn24TWM2OD12Nj61NkBvVQ>?	MmGwV2FPT0WU
PC-14	NH\uTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7yXIdKSzVyPUS2MlU4KG6P	MnnNV2FPT0WU
TE-5	M1vibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHuwWXlKSzVyPUS2Mlg1KG6P	NHfaUZZUSU6JRWK=
LB996-RCC	NHzJd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LHOGlEPTB;NEeuNVkhdk1?	NGTafpdUSU6JRWK=
NCI-H1623	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Hqe2lEPTB;NEeuO\|Yhdk1?	MmLFV2FPT0WU
NCI-H1155	NXXHc45HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zhN2lEPTB;NEiuN\|Ihdk1?	MVrTRW5ITVJ?
LoVo	NHHHeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLqS5pKSzVyPUS4MlQhdk1?	NXLST\|l4W0GQR1XS
MCF7	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DZRWlEPTB;NEiuOVghdk1?	NIjJZXRUSU6JRWK=
AGS	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTR6Lke3JI5O	M1rwRXNCVkeHUh?=
PFSK-1	NHfQ[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTQVXBpUUN3ME20PU4xPiCwTR?=	MX7TRW5ITVJ?
22RV1	NWL2dYFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTR7LkC5JI5O	NED6PJdUSU6JRWK=
COR-L23	NWTYRVV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVm0UFFRUUN3ME20PU4yPiCwTR?=	MoO1V2FPT0WU
D-283MED	NH;lWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXlXm1VUUN3ME20PU43OSCwTR?=	Mn;NV2FPT0WU
SW982	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzReIlKSzVyPUS5MlkyKG6P	NEnBc\|BUSU6JRWK=
SW620	NULTSIpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTVyLkO2JI5O	M3TPe3NCVkeHUh?=
KYSE-140	M3HRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLLOpNKSzVyPUWwMlU2KG6P	NHHoXWFUSU6JRWK=
GCIY	NUn5TmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHU[IZKSzVyPUWwMlY4KG6P	NYf3[IQ3W0GQR1XS
MHH-ESS-1	NYTwOYg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nmc2lEPTB;NUGuPVUhdk1?	MmjOV2FPT0WU
D-423MG	M3Hhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrJTWM2OD13Mj6wPEBvVQ>?	M3r5dXNCVkeHUh?=
SF539	NFXKTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTV{LkO1JI5O	NYPFUlhbW0GQR1XS
RPMI-2650	NF21[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\2TWM2OD13Mj62PUBvVQ>?	MmDlV2FPT0WU
GR-ST	NVPPPFZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrVWIJkUUN3ME21Nk45PyCwTR?=	MnjyV2FPT0WU
YKG-1	M4n2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITwUlNKSzVyPUWzJI5O	MlntV2FPT0WU
SK-MES-1	NFPWVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHWPFVKSzVyPUWzMlI3KG6P	MXTTRW5ITVJ?
HLE	MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTBW3pKSzVyPUWzMlQ4KG6P	MXjTRW5ITVJ?
RVH-421	NHvhPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTV\|Lk[3JI5O	NGfubW1USU6JRWK=
C32	NW\Ib5FXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zoU2lEPTB;NUOuPFMhdk1?	MojuV2FPT0WU
GB-1	NHLDWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTV2LkKgcm0>	MUnTRW5ITVJ?
SNB75	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz3e2xOUUN3ME21OE4zPiCwTR?=	NUG5SFk5W0GQR1XS
EM-2	M4\Y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjpWINKSzVyPUW0MlQhdk1?	Mn;yV2FPT0WU
RH-1	MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TKcGlEPTB;NUSuO{BvVQ>?	MXPTRW5ITVJ?
NKM-1	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDjTWM2OD13ND64NUBvVQ>?	M4HyS3NCVkeHUh?=
NCI-H2405	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnFTWM2OD13ND64PEBvVQ>?	MXnTRW5ITVJ?
KYSE-450	MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFy4UWNKSzVyPUW1MlE3KG6P	NW\GOHpbW0GQR1XS
A704	M4DKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojCTWM2OD13NT61PUBvVQ>?	MWrTRW5ITVJ?
HAL-01	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7oSllKSzVyPUW1Mlg{KG6P	M{i4O3NCVkeHUh?=
TE-11	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTV3Lkm5JI5O	NV[4UGNwW0GQR1XS
DOK	NWjue4ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfUTWM2OD13Nj6wNkBvVQ>?	NH[4cVlUSU6JRWK=
KY821	Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rhN2lEPTB;NU[uNkBvVQ>?	Mn3YV2FPT0WU
KGN	M1LOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fxbGlEPTB;NU[uN\|Ihdk1?	M4q4bXNCVkeHUh?=
MC116	MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXJVGZKSzVyPUW3Mlghdk1?	M2XOU3NCVkeHUh?=
PANC-08-13	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXYd4VKSzVyPUW4MlAyKG6P	NXzaTWNvW0GQR1XS
KE-37	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHTTWM2OD13OD63O{BvVQ>?	M2TtO3NCVkeHUh?=
KYSE-410	M4jl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4O5SWlEPTB;NUmuOFchdk1?	M{TENnNCVkeHUh?=
RO82-W-1	NWPTb2FST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4T0VGlEPTB;NUmuPUBvVQ>?	MmXSV2FPT0WU
M14	MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\kTWM2OD14MD6wOEBvVQ>?	M4fwWXNCVkeHUh?=
GI-1	MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTZyLkOgcm0>	NGnWO\|ZUSU6JRWK=
ML-2	NEDmOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TZ[2lEPTB;NkCuOlIhdk1?	NIXlZpNUSU6JRWK=
BFTC-905	NHTEVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTZyLk[1JI5O	MWnTRW5ITVJ?
DMS-273	NYPmemU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTZyLki3JI5O	NGjEb2RUSU6JRWK=
MDA-MB-361	NITGWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTZzIH7N	NYKxPGpTW0GQR1XS
MSTO-211H	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnuVoJKSzVyPU[zMlUyKG6P	M4HC[HNCVkeHUh?=
MEG-01	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PKcWlEPTB;NkOuOVIhdk1?	Ml[yV2FPT0WU
M059J	MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7mXY84UUN3ME22N{42QCCwTR?=	NUS0NlBMW0GQR1XS
LN-405	NWPpXlk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPYTWM2OD14Mz64OUBvVQ>?	MoTJV2FPT0WU
NCI-H1581	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXKwcFFpUUN3ME22OE4xOyCwTR?=	Mo\aV2FPT0WU
TCCSUP	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLRdIJKSzVyPU[0MlU{KG6P	M1m0Z3NCVkeHUh?=
SW872	NUTub2F7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfrd5JKSzVyPU[0MlU4KG6P	M4eyV3NCVkeHUh?=
KYSE-510	NF7PeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIriN5ZKSzVyPU[1Mlc2KG6P	MX;TRW5ITVJ?
NCI-H1792	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFj0[XVKSzVyPU[2MlE2KG6P	NF7GT3NUSU6JRWK=
SW13	NGD3W3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\NUGlEPTB;Nk[uOUBvVQ>?	Mn;nV2FPT0WU
TE-8	NFq4dIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVn2[5ZOUUN3ME22Ok42OiCwTR?=	NV\vR\|BEW0GQR1XS
SCH	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHCNodKSzVyPU[3MlEhdk1?	MVnTRW5ITVJ?
NEC8	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\tTWM2OD14Nz6yOEBvVQ>?	MkHFV2FPT0WU
HuO-3N1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXVc4NuUUN3ME22O{4{OSCwTR?=	MWfTRW5ITVJ?
EFM-19	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVv2Sm4xUUN3ME22O{42KG6P	MYTTRW5ITVJ?
HEC-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXWzNmhFUUN3ME22O{42OiCwTR?=	M3y2U3NCVkeHUh?=
T47D	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3wNoVKSzVyPU[3Mlg4KG6P	MV7TRW5ITVJ?
SNU-423	NYW0[XlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTZ5Lkm4JI5O	NU\LU2pVW0GQR1XS
WM-115	NVjxVVFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PncmlEPTB;NkiuNVQhdk1?	NXXZdXZsW0GQR1XS
CaR-1	NF3tfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTMT29oUUN3ME22PE4zPSCwTR?=	Mn34V2FPT0WU
KU812	M3jmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTZ6Lk[5JI5O	MWPTRW5ITVJ?
AM-38	NGq4SoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvDTWM2OD14OT6zNUBvVQ>?	NVr4PHl4W0GQR1XS
KOSC-2	M3rpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzC[ItyUUN3ME22PU46PyCwTR?=	NHXxT3hUSU6JRWK=
MC-IXC	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTdyLkC4JI5O	M4X1NXNCVkeHUh?=
SCC-4	M3u0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTdzLkO4JI5O	NVPpfIFnW0GQR1XS
Calu-3	NXLmbXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrkTWM2OD15MT65PEBvVQ>?	M3vLO3NCVkeHUh?=
RPMI-8866	Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTd{LkiyJI5O	M2fRbHNCVkeHUh?=
OVCAR-4	NFrjRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTd\|LkO2JI5O	MXXTRW5ITVJ?
OAW-42	M1HoWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTwRmw6UUN3ME23N{4{QSCwTR?=	NIfsTJhUSU6JRWK=
ATN-1	M13l[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTd\|Lki3JI5O	MonlV2FPT0WU
CHP-212	NX;HbpVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYX5R3RQUUN3ME23OE46PSCwTR?=	M1Lxd3NCVkeHUh?=
C2BBe1	M3PFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTd3LkCzJI5O	MofqV2FPT0WU
A498	M3HX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTd3LkG1JI5O	MWXTRW5ITVJ?
SH-4	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mle1TWM2OD15NT6yNUBvVQ>?	MlvPV2FPT0WU
SNU-449	MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkC0TWM2OD15NT63PUBvVQ>?	M{j5RnNCVkeHUh?=
RD	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHOV4pKSzVyPUe1Mlg3KG6P	NV;4[VU1W0GQR1XS
PANC-03-27	NWP0T2pFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmn4TWM2OD15Nj6yOUBvVQ>?	NEGybo9USU6JRWK=
S-117	NU\XclZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPkRplKSzVyPUe2MlI4KG6P	Mki0V2FPT0WU
SK-MEL-2	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLnR2lKSzVyPUe2Mlc2KG6P	NYrzSXBEW0GQR1XS
LK-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoH5TWM2OD15Nz6wOUBvVQ>?	MnW4V2FPT0WU
CP50-MEL-B	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LxZmlEPTB;N{euOEBvVQ>?	MUjTRW5ITVJ?
647-V	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4P2dmlEPTB;N{iuNFchdk1?	M4O2V3NCVkeHUh?=
LU-134-A	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnSfmVPUUN3ME23PU4xOyCwTR?=	NITXdphUSU6JRWK=
5637	NX\oSXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPKeod1UUN3ME23PU4zOyCwTR?=	NHnyXG9USU6JRWK=
NCI-H1437	NH;3cW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfuZop3UUN3ME24NE42KG6P	NH7US\|ZUSU6JRWK=
NCI-H460	M1e4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXhZpVKSzVyPUixMlI{KG6P	Mnr6V2FPT0WU
BxPC-3	NW[2bm5pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRThzLkS2JI5O	NX:wb2w3W0GQR1XS
CAN	M3\ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUj0dFFtUUN3ME24NU45PCCwTR?=	MXnTRW5ITVJ?
KINGS-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\z[HVKSzVyPUiyMlMzKG6P	MYPTRW5ITVJ?
OCUB-M	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTh{LkSxJI5O	NWi5XZJLW0GQR1XS
KALS-1	M2rsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmKwTWM2OD16Mj61OEBvVQ>?	NYnidYE6W0GQR1XS
OCI-AML2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPJZoJKSzVyPUiyMlYyKG6P	M1ziTnNCVkeHUh?=
A253	MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LWWWlEPTB;OEKuOlUhdk1?	M4HDNHNCVkeHUh?=
LCLC-97TM1	M1Pmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTh{Lki2JI5O	MnvyV2FPT0WU
NCI-H520	M4TpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHG0fnVKSzVyPUizMlA3KG6P	NIDlSFlUSU6JRWK=
P30-OHK	M{GzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[wSGVKSzVyPUizMlUhdk1?	MojOV2FPT0WU
SBC-5	NULHbHVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPvfZU4UUN3ME24N{42OiCwTR?=	Ml64V2FPT0WU
HCE-T	M4nMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXjToVUUUN3ME24N{44PCCwTR?=	MXHTRW5ITVJ?
JEG-3	M4DkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3mwdmlEPTB;OESuNUBvVQ>?	MVvTRW5ITVJ?
KG-1	M3nDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnH5TWM2OD16ND6yOEBvVQ>?	MUfTRW5ITVJ?
MIA-PaCa-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDuTWM2OD16ND61OEBvVQ>?	NYC4RYRpW0GQR1XS
CAL-33	NVTlT21uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTyTWM2OD16NT6wPEBvVQ>?	NWDT[4dZW0GQR1XS
639-V	MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrYUZVrUUN3ME24OU41OiCwTR?=	MlnOV2FPT0WU
NCI-H1048	M2XzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVK4UJUyUUN3ME24Ok4{OSCwTR?=	MoDWV2FPT0WU
NCI-H1573	MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Lpd2lEPTB;OEeuOFghdk1?	M{f5b3NCVkeHUh?=
NCI-H2228	M2LYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTQTWM2OD16OD6yOkBvVQ>?	NHLjW2RUSU6JRWK=
NB14	NWjIcnZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrpTWM2OD16OD6zJI5O	M2D6V3NCVkeHUh?=
SCC-25	NFzGfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGC4b\|FKSzVyPUi5MlgzKG6P	MYXTRW5ITVJ?
A431	NFjNdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTZSGVtUUN3ME24PU46PyCwTR?=	NYe5UFRwW0GQR1XS
SN12C	M1L4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17uVGlEPTB;OUCuOlIhdk1?	MVTTRW5ITVJ?
HuCCT1	M4\SbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLxTWM2OD17MD63OkBvVQ>?	M13PVXNCVkeHUh?=
LS-123	NWPzUo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnWRW9KSzVyPUmyMlE5KG6P	MV\TRW5ITVJ?
CAL-85-1	NGnpNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3Tne2lEPTB;OUKuOFghdk1?	MWfTRW5ITVJ?
ES6	Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPnTWM2OD17Mj64N{BvVQ>?	NIeyWYlUSU6JRWK=
NCI-H650	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1Lab2lEPTB;OUSuNFkhdk1?	M3jTSXNCVkeHUh?=
NCI-H446	M3LRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHnTWM2OD17NT6xNkBvVQ>?	M4riRnNCVkeHUh?=
EW-13	NV;Le4tbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTl3Lke1JI5O	NV7FRYwzW0GQR1XS
HSC-2	M3;vPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTkWY85UUN3ME25OU45QSCwTR?=	NEO4WnJUSU6JRWK=
U031	NXPhXm5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTl4LkezJI5O	MWfTRW5ITVJ?
EW-11	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXteG5HUUN3ME25Ok45QCCwTR?=	NXjPbpZRW0GQR1XS
GAK	M{PWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3FTWM2OD17OD65N{BvVQ>?	NVP4OFVXW0GQR1XS
SK-OV-3	NVftTo8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF20VJZKSzVyPUGwNE4xPyCwTR?=	NGLWXItUSU6JRWK=
OMC-1	MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnzTWM2OD1zMECuNVghdk1?	M{LpTHNCVkeHUh?=
TK10	M1HITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TuW2lEPTB;MUCwMlIyKG6P	MWPTRW5ITVJ?
EKVX	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnsVldKSzVyPUGwNE43KG6P	M{PRVXNCVkeHUh?=
Detroit562	NFP6[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHYTWM2OD1zMEKuNVchdk1?	MlPVV2FPT0WU
SF268	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHztd4VKSzVyPUGwNk4{PCCwTR?=	MkTIV2FPT0WU
SNU-387	M2LRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHmS5FbUUN3ME2xNFQvOTdibl2=	NWfjV213W0GQR1XS
MDA-MB-231	MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTFyNT6wOkBvVQ>?	MoLUV2FPT0WU
NCI-H1563	M3LETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvKW2VKSzVyPUGwOU4yQCCwTR?=	M3O0VHNCVkeHUh?=
D-502MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEn2OoVKSzVyPUGwOU44KG6P	M3;VOXNCVkeHUh?=
A2780	NGn5ZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFu0cm1KSzVyPUGwOk41PyCwTR?=	M1u0d3NCVkeHUh?=
IA-LM	NHTNTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTMeIZlUUN3ME2xNFcvPTFibl2=	MljXV2FPT0WU
D-392MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvFTWM2OD1zMEeuOVQhdk1?	MXLTRW5ITVJ?
MS-1	Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPZXXNsUUN3ME2xNFcvPzFibl2=	MVjTRW5ITVJ?
SW1990	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfwVpY5UUN3ME2xNFgvPTRibl2=	M130WnNCVkeHUh?=
HEL	Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzaZ4ZGUUN3ME2xNFkvOjlibl2=	NXnnVoNnW0GQR1XS
SW1573	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PMOmlEPTB;MUC5MlMyKG6P	Mni1V2FPT0WU
SW1783	MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFzMD6yNkBvVQ>?	MoXCV2FPT0WU
COLO-680N	NFjOV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTFzMD63OkBvVQ>?	NGjOU45USU6JRWK=
NCI-N87	NXji[G52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvPOm5YUUN3ME2xNVEvODRibl2=	NHHVT4JUSU6JRWK=
SK-MEL-28	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFzMT61OUBvVQ>?	Mlr2V2FPT0WU
BT-20	NWi4Z4VuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\aTWM2OD1zMUKuNFEhdk1?	NI\y[3hUSU6JRWK=
NCI-H1648	NHLwT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTFzMzDuUS=>	M3vTSnNCVkeHUh?=
no-11	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW[4PXVzUUN3ME2xNVMvOjhibl2=	MmjUV2FPT0WU
MOLT-13	NVvIdlBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\JZ3pKSzVyPUGxN{41PCCwTR?=	MlfIV2FPT0WU
NCI-H2170	NX7yVGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPLW4NKSzVyPUGxOE42OSCwTR?=	MUjTRW5ITVJ?
HTC-C3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLSSGhyUUN3ME2xNVYvQDVibl2=	M{TOeHNCVkeHUh?=
LU-99A	NX;XO5VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;0UmlEPTB;MUG3MlIyKG6P	MYHTRW5ITVJ?
HCC2998	MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLvTWM2OD1zMUeuPVIhdk1?	MlntV2FPT0WU
NB13	NHrRUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HFWmlEPTB;MUG3Mlk6KG6P	MXnTRW5ITVJ?
GT3TKB	NX;OSpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1:2SGlEPTB;MUG4MlA5KG6P	NHXvdnlUSU6JRWK=
BT-549	M3LuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:wb5RKSzVyPUGxPE46PSCwTR?=	NYPIUW05W0GQR1XS
NCI-H747	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDGfodKSzVyPUGxPU4{PCCwTR?=	NEfkO5BUSU6JRWK=
EW-1	NInncoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jweWlEPTB;MUKwMlIhdk1?	NYnCO\|g6W0GQR1XS
LB831-BLC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[yeGlEPTB;MUKwMlY{KG6P	M2fCPXNCVkeHUh?=
NMC-G1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDBWHdHUUN3ME2xNlEvOTFibl2=	M1KyVXNCVkeHUh?=
COLO-679	NHPvfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTF{Mj6xOUBvVQ>?	NYHHWXo{W0GQR1XS
HL-60	NHnmNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mof2TWM2OD1zMkOuNUBvVQ>?	MU\TRW5ITVJ?
MKN7	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTF{Mz64N{BvVQ>?	MU\TRW5ITVJ?
RERF-LC-MS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjxfZlKSzVyPUGyOE4{OSCwTR?=	NHm0bJRUSU6JRWK=
DMS-114	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz3eldlUUN3ME2xNlUvODlibl2=	MmLuV2FPT0WU
HuP-T4	NVHEPGhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLITWM2OD1zMk[uPVchdk1?	NIfZU2xUSU6JRWK=
HCC2157	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\w[mlEPTB;MUK3MlUhdk1?	MmDMV2FPT0WU
SKG-IIIa	NVTHendmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnINYFyUUN3ME2xNlgvQCCwTR?=	NGLuWW5USU6JRWK=
HCT-116	NFXZXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mne4TWM2OD1zM{CuOlQhdk1?	NWXy[oN2W0GQR1XS
BB30-HNC	NWTKbolOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\DTWM2OD1zM{CuO\|ghdk1?	M13Ib3NCVkeHUh?=
KYSE-270	MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTF\|MD64PEBvVQ>?	Mn;PV2FPT0WU
MFM-223	NE\6b25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPXTWM2OD1zM{GuOVEhdk1?	MmnqV2FPT0WU
NH-12	NELZb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjse\|BKSzVyPUGzNk46QSCwTR?=	M{ftOXNCVkeHUh?=
U-118-MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;YdIZiUUN3ME2xN\|MvPjJibl2=	MWLTRW5ITVJ?
ESS-1	Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHxNFBKSzVyPUGzOU4yQCCwTR?=	M4jOUHNCVkeHUh?=
D-247MG	NIfud\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmCxTWM2OD1zM{WuNlEhdk1?	MWDTRW5ITVJ?
IGROV-1	NVLDdWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTF\|NT63OkBvVQ>?	M3XYNHNCVkeHUh?=
C-33-A	NXnFd24zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkT6TWM2OD1zM{WuPVchdk1?	M1nMUXNCVkeHUh?=
NCI-H1693	MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\TbIdKSzVyPUGzOk4yOiCwTR?=	NHvaS29USU6JRWK=
MLMA	M4X3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHtNJN1UUN3ME2xN\|YvPThibl2=	NXvoW\|l{W0GQR1XS
SK-N-AS	MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7WZo5KSzVyPUGzO{4yPyCwTR?=	NEDxWJdUSU6JRWK=
NCI-H1755	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDMTWM2OD1zM{iuPFUhdk1?	NEL4T4hUSU6JRWK=
CHP-134	NF;WTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\ETWM2OD1zM{muOVUhdk1?	NUHNVol{W0GQR1XS
LS-513	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTF2MD65NUBxVQ>?	NVHLZpliW0GQR1XS
TE-12	MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkm3TWM2OD1zNECuPVMhdk1?	MlW3V2FPT0WU
KNS-42	NIjOcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHVTWM2OD1zNESuN{BvVQ>?	MVvTRW5ITVJ?
SJRH30	NI\XOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfO[3lKSzVyPUG0OE41PCCwTR?=	NWHqd5A5W0GQR1XS
NCI-H1092	NEDPb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfudXFKSzVyPUG0OE42OiCwTR?=	MWXTRW5ITVJ?
H-EMC-SS	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrIUlNTUUN3ME2xOFYvQDFibl2=	MXPTRW5ITVJ?
SK-MEL-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTF2Nz61OUBvVQ>?	M4[zdXNCVkeHUh?=
SK-N-FI	NYWw[3BST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLIVYo2UUN3ME2xOFcvPTlibl2=	MX3TRW5ITVJ?
NCI-H2126	NWjycZpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTF2OD6xOUBvVQ>?	MYjTRW5ITVJ?
NCI-H1299	NEPQU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3m[pNKSzVyPUG1NE4zOiCwTR?=	M2XNTHNCVkeHUh?=
CFPAC-1	NFX3[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3r1NGlEPTB;MUWwMlY3KG6P	MoDZV2FPT0WU
NCI-H661	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX0[YVKSzVyPUG1NU4zPiCwTR?=	NH\LXFlUSU6JRWK=
KYSE-70	NX7lOoZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUL4VYRJUUN3ME2xOVEvPzlibl2=	M33Xd3NCVkeHUh?=
SW900	MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfnRWJKSzVyPUG1OE43PSCwTR?=	M2\UVHNCVkeHUh?=
Ca-Ski	MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkH0TWM2OD1zNU[uN\|khdk1?	NEn4e5JUSU6JRWK=
HPAF-II	M4fuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LjR2lEPTB;MUW2MlQ4KG6P	M4rmenNCVkeHUh?=
LB2518-MEL	M1PXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTF3Nz6xJI5O	Mkn2V2FPT0WU
LC-2-ad	NI\vRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTGTWM2OD1zNUiuOlIhdk1?	MY\TRW5ITVJ?
HCC1806	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHzOGJKSzVyPUG2O{45QCCwTR?=	NWW2PFE3W0GQR1XS
UACC-62	NFL1VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmL0TWM2OD1zNkiuNFkhdk1?	Ml:xV2FPT0WU
KM-H2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3P2d2lEPTB;MUewMlU5KG6P	M1fxNHNCVkeHUh?=
NCI-H2347	NF7BV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{W1SGlEPTB;MUeyMlczKG6P	MXHTRW5ITVJ?
SCC-15	MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfVeGlNUUN3ME2xO\|MvPjZibl2=	M1LhV3NCVkeHUh?=
BB49-HNC	NF25NnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnGT\|FVUUN3ME2xO\|MvQDFibl2=	NUf3[5M{W0GQR1XS
GMS-10	Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGT4RYxKSzVyPUG3N{46PCCwTR?=	M{n3c3NCVkeHUh?=
NCI-H2052	MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3W5NGlEPTB;MUe0Mlkhdk1?	M2\Oe3NCVkeHUh?=
SW626	M3[yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MniwTWM2OD1zN{[uNFYhdk1?	NGDPXFhUSU6JRWK=
MDA-MB-415	NVHMfWZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\6OGlEPTB;MUe2MlYyKG6P	NXX5U\|RTW0GQR1XS
Saos-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\kS2lEPTB;MUe5MlM2KG6P	Ml3VV2FPT0WU
DK-MG	NWTTNWc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLpTWM2OD1zOECuN{BvVQ>?	Ml3wV2FPT0WU
SNU-C2B	MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTKVZdPUUN3ME2xPFAvPzNibl2=	M1LIZnNCVkeHUh?=
A427	MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TTNmlEPTB;MUiyMlU4KG6P	NUnKe\|loW0GQR1XS
KP-N-YS	NHeydWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnDS5psUUN3ME2xPFUhdk1?	MkPzV2FPT0WU
J82	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGD3Vo9KSzVyPUG4OU4yQCCwTR?=	M2C2fHNCVkeHUh?=
LS-411N	M{Th[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF6Nz6yPEBvVQ>?	MkXHV2FPT0WU
HCC1937	NXn4Um5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnx[oZTUUN3ME2xPFcvPDlibl2=	NVHPOJdxW0GQR1XS
OE33	NULXPXpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LxV2lEPTB;MUi4Mlk4KG6P	MW\TRW5ITVJ?
NB7	NXz4PFBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\S[2lEPTB;MUi5Mlg6KG6P	NFThcotUSU6JRWK=
SW684	NIfoRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjWd4tKSzVyPUG5Ok4yOyCwTR?=	NVTHUlVKW0GQR1XS
HT-144	NVnud\|Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nMbWlEPTB;MUm2MlE2KG6P	MWrTRW5ITVJ?
SK-MEL-30	NUHnUXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVOxNFRJUUN3ME2xPVYvOiCwTR?=	M1LlT3NCVkeHUh?=
DBTRG-05MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTF7OD60O{BvVQ>?	NWTMWVFjW0GQR1XS
NCI-H1395	MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVOxTYNOUUN3ME2xPVgvQDVibl2=	MoPIV2FPT0WU
NCI-H2122	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTJyMD61PUBvVQ>?	NHXHfHZUSU6JRWK=
no-10	M1T3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJyMT6wOEBvVQ>?	NHLOUlZUSU6JRWK=
SW48	M{PwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDDOnF[UUN3ME2yNFEvOzFibl2=	MljOV2FPT0WU
NCI-H1650	NUHjdmlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvBW5FpUUN3ME2yNFQvODFibl2=	NFLiUZRUSU6JRWK=
MZ1-PC	NYHxWI0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEf1e\|hKSzVyPUKwOU42QCCwTR?=	NYLx[HRIW0GQR1XS
U-266	M1jBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHqzU5VKSzVyPUKwOU44QSCwTR?=	NXHrPGpIW0GQR1XS
CAS-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moe3TWM2OD1{MEeuOFQhdk1?	MV7TRW5ITVJ?
AU565	NFnj[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7aVYRKSzVyPUKxNk45OiCwTR?=	NEnqXlRUSU6JRWK=
UACC-257	MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nnemlEPTB;MkGzMlk6KG6P	M3rVZXNCVkeHUh?=
CAL-27	NF3XUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmSxTWM2OD1{MUeuNFUhdk1?	MVrTRW5ITVJ?
NCI-H23	M2rKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3EeXdKSzVyPUKxPU4{OyCwTR?=	MU\TRW5ITVJ?
TE-6	MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13Sc2lEPTB;MkG5MlY5KG6P	MmPFV2FPT0WU
TGBC24TKB	NHTwT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HmRWlEPTB;MkKyMlE4KG6P	MmjEV2FPT0WU
TE-1	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTJ{Mj64PEBvVQ>?	Mn\MV2FPT0WU
RCC10RGB	NVyzSFFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDVTWM2OD1{MkSuNVkhdk1?	M1\kT3NCVkeHUh?=
NCI-H596	M{fzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWS1R3NtUUN3ME2yNlgvOjJibl2=	NWHQfmE5W0GQR1XS
SW954	MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLXTWM2OD1{M{OuPFMhdk1?	MnOwV2FPT0WU
NCI-H2087	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXB[m5PUUN3ME2yN\|QvPTFibl2=	MoP6V2FPT0WU
SK-PN-DW	MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTJ\|NT6xPUBvVQ>?	NYHlTHRVW0GQR1XS
KM12	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrwfohKSzVyPUKzOU44KG6P	M2n3RXNCVkeHUh?=
BT-474	Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTJ\|NT63N{BvVQ>?	NXL6bFVqW0GQR1XS
IST-MES1	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTJ\|Nj61O{BvVQ>?	NXzKfnp[W0GQR1XS
HT-1197	NFXxOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJ\|OD6wPUBvVQ>?	MXrTRW5ITVJ?
CAL-54	NYTmXYhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTBTWM2OD1{M{iuOFkhdk1?	M3PId3NCVkeHUh?=
NB10	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLCcGJwUUN3ME2yOFAvODZibl2=	NXT3flUzW0GQR1XS
PANC-10-05	M{Gy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYmxTWJQUUN3ME2yOFUvPTZibl2=	MVXTRW5ITVJ?
NCI-H522	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDPTWM2OD1{NEiuN\|Ehdk1?	NEPxfINUSU6JRWK=
A388	M4TqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XwPWlEPTB;MkS5MlgzKG6P	M125W3NCVkeHUh?=
GOTO	M17MW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mon5TWM2OD1{NUCuNlkhdk1?	NGXMN\|FUSU6JRWK=
KLE	NYi1XnlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTtflRwUUN3ME2yOVEvQDdibl2=	NFHTWGhUSU6JRWK=
KYSE-520	M4\Sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJ3Mj64OkBvVQ>?	NV3zdGU3W0GQR1XS
HCE-4	M{DZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPwTWM2OD1{NkKuOUBvVQ>?	Mk[zV2FPT0WU
KURAMOCHI	M4rtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFmyWGlKSzVyPUK2OU46KG6P	MWLTRW5ITVJ?
HCC38	NEPUelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTJ4Nj60PEBvVQ>?	MlrvV2FPT0WU
FADU	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2WzNGlEPTB;Mk[2MlY{KG6P	MV;TRW5ITVJ?
CW-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfhNphOUUN3ME2yOlkvQTZibl2=	MYLTRW5ITVJ?
L-428	NGH4bFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjYZY5QUUN3ME2yO\|UvOTVibl2=	M2C1V3NCVkeHUh?=
HCC1569	MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTJ5NT64OEBvVQ>?	NGPQ[nhUSU6JRWK=
NCI-H810	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJ5OD6zNUBvVQ>?	NG\TSVFUSU6JRWK=
LB771-HNC	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\IeXhjUUN3ME2yPFUvQDRibl2=	NVP2T5BGW0GQR1XS
LCLC-103H	NYfvW21MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIro[2ZKSzVyPUK4OU46QSCwTR?=	Ml[xV2FPT0WU
EFO-21	M4P4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3voWWlEPTB;Mki3MlY5KG6P	NWPj[41YW0GQR1XS
CAL-72	NWLlPY1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEmwUFhKSzVyPUK5N{4yQSCwTR?=	NWPoPHIzW0GQR1XS
SCC-9	MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XSfGlEPTB;MkmzMlIzKG6P	M4TsOnNCVkeHUh?=
COLO-829	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LtUWlEPTB;Mkm2MlUhdk1?	MknWV2FPT0WU
U-87-MG	NGLiPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfHTnc3UUN3ME2zNFAvPzNibl2=	NYXI[ItLW0GQR1XS
MZ7-mel	NF3EXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M32xZmlEPTB;M{KzMlc3KG6P	MnXpV2FPT0WU
NCI-H1770	NXrNd2wxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTN{Nj63OEBvVQ>?	MUDTRW5ITVJ?
ChaGo-K-1	NHPIV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUf0XYJQUUN3ME2zNlgvOSCwTR?=	Mo\sV2FPT0WU
SiHa	MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\uTWM2OD1\|MkmuNlQhdk1?	M1fxS3NCVkeHUh?=
NCI-SNU-5	M1TNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHZV5ZKSzVyPUOzOk44PyCwTR?=	Mn\XV2FPT0WU
DJM-1	NUS5VVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mni1TWM2OD1\|NECuN\|Mhdk1?	Mk\IV2FPT0WU
OE19	M17qd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3Lk[2lEPTB;M{SwMlU{KG6P	NHHiVI5USU6JRWK=
NCI-H1651	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7sTWM2OD1\|NESuNVghdk1?	M{OzPHNCVkeHUh?=
COLO-792	NH\OSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTZUIp5UUN3ME2zOVQvPDJibl2=	MmXtV2FPT0WU
ACHN	NUfEVFc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLEe4pKSzVyPUO1Ok44OSCwTR?=	M4\Db3NCVkeHUh?=
TH-3	NF\DXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTN5OT65OUBvVQ>?	NWrzSFFPW0GQR1XS
HT-1376	M3GxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHe3RXBKSzVyPUO4OE45QCCwTR?=	MljzV2FPT0WU
RH-18	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInBdlZKSzVyPUO5OE44PCCwTR?=	MXPTRW5ITVJ?
NB6	M2POe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTN7Nj62OkBvVQ>?	MWXTRW5ITVJ?
COLO-320-HSR	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rReGlEPTB;NECzMlM4KG6P	MnzLV2FPT0WU
UACC-893	M1PKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17HeWlEPTB;NEC2MlQ4KG6P	MXzTRW5ITVJ?
DSH1	MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7EOHZKSzVyPUSwOk46OSCwTR?=	M4fqUnNCVkeHUh?=
TE-10	MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPQc5B[UUN3ME20NFcvODFibl2=	MXzTRW5ITVJ?
HCC70	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTRyOT6yNUBvVQ>?	NXX0eIk4W0GQR1XS
TGBC11TKB	NVLGS45LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTRzMD6zN{BvVQ>?	MmC4V2FPT0WU
NCI-H727	NXezVmJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnTTWM2OD12MUKuNVEhdk1?	MYTTRW5ITVJ?
ALL-PO	M1THSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LKTWlEPTB;NEG1MlY6KG6P	MnHOV2FPT0WU
ABC-1	Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXBTWM2OD12MkCuOFUhdk1?	NGmzflJUSU6JRWK=
NCI-H69	NUSwb3JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1y1eGlEPTB;NEK2Mlc3KG6P	NFzuR4pUSU6JRWK=
GP5d	NUXPSXdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjo[XAzUUN3ME20N\|QvPDFibl2=	NVjD[FN2W0GQR1XS
UMC-11	MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDpT5BKSzVyPUS1PE4{PiCwTR?=	NWrhcWZWW0GQR1XS
RMG-I	NUHwSIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTR4Nz61OkBvVQ>?	Mmi1V2FPT0WU
YAPC	NIPlUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTR7MD62JI5O	MkjwV2FPT0WU
LS-1034	Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTMTWM2OD12OUGuNFYhdk1?	MYXTRW5ITVJ?
RCM-1	MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTLTWM2OD12OU[uOlghdk1?	MlHYV2FPT0WU
HCC1954	NVPmNldQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\LTWM2OD13MUKuOUBvVQ>?	M{m2V3NCVkeHUh?=
SK-MEL-24	NWXKc3NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITnW21KSzVyPUWxOk42OSCwTR?=	NGHJSGZUSU6JRWK=
NB12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX3dYJKSzVyPUWyPE41OiCwTR?=	Mn3ZV2FPT0WU
SW756	M1XnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTV3ND65OkBvVQ>?	NITLdYxUSU6JRWK=
HCC1187	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLqcW5KSzVyPUW3OU45OyCwTR?=	NHr4eXVUSU6JRWK=
NCI-H2342	NFy4bnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPJcZFKSzVyPUW5NE4{QSCwTR?=	NEjVXJNUSU6JRWK=
NCI-H2291	MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWKyNoxUUUN3ME21PVgvOzFibl2=	NVT0WVM4W0GQR1XS
OVCAR-3	NYm1SGpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;ObYFKSzVyPUW5PE46PiCwTR?=	NE\wbVBUSU6JRWK=
MHH-NB-11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXObosxUUN3ME22NlkvODFibl2=	M3;TXXNCVkeHUh?=
SAS	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzGTWM2OD14NUKuOlchdk1?	MoPCV2FPT0WU
COLO-824	NUHQdZhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTZ6OT6zO{BvVQ>?	MVTTRW5ITVJ?
HCC1395	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\yfWlEPTB;Nkm4MlUhdk1?	M1zucXNCVkeHUh?=
COLO-668	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rX[2lEPTB;N{C2MlEhdk1?	M2DzbHNCVkeHUh?=
NCI-H226	M4\DVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3z3cmlEPTB;N{C3Mlghdk1?	M3PKV3NCVkeHUh?=
NB17	M2nw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jIO2lEPTB;N{KxMlc2KG6P	Mn\TV2FPT0WU
SW1463	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTd\|OT6xPUBvVQ>?	M2\vUXNCVkeHUh?=
TGW	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvMTWM2OD15NkCuNVUhdk1?	M1r3NXNCVkeHUh?=
NCI-H526	MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDRbpZFUUN3ME24NlMvPTNibl2=	NF70[oxUSU6JRWK=
COR-L88	NWjVRlRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jVbmlEPTB;OES4MlEzKG6P	NXvrcW1iW0GQR1XS
NCI-H441	NUizb4RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fVeGlEPTB;OEm1MlIzKG6P	NV3nco9IW0GQR1XS
NCI-H630	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zyNmlEPTB;OUGyMlk3KG6P	M3;PVnNCVkeHUh?=
Mo-T	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHpTWM2OD17NEeuPFghdk1?	MUHTRW5ITVJ?
JAR	M{PYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHwdZVOUUN3ME25OVYvOjRibl2=	Mk\DV2FPT0WU
NCI-H1838	Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfPTWM2OD1zLkCyN\|g5KM7:TR?=	NUHrNopMW0GQR1XS
DoTc2-4510	NUDxXIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HPRWlEPTB;MT6wO\|M4PiEQvF2=	MnrvV2FPT0WU
MKN28	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml:0TWM2OD1zLkC5NFI1KM7:TR?=	NHfGd2xUSU6JRWK=
HuP-T3	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYexeIk6UUN3ME2xMlEyQTB3IN88US=>	MoHiV2FPT0WU
TE-9	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\mfIdKSzVyPUGuNVI6PzNizszN	MnnrV2FPT0WU
NY	NWHmTnllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DEZWlEPTB;MT6xOlc6OiEQvF2=	NIGy[XJUSU6JRWK=
HT55	MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vpeWlEPTB;MT6zNVM1PCEQvF2=	NWLp[npMW0GQR1XS
SW837	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfSTWM2OD1zLkOyPVc5KM7:TR?=	NV3MXIVmW0GQR1XS
NCI-H2029	NGC0T4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTFwNEG3PVEh\|ryP	NHvBWXBUSU6JRWK=
IST-SL1	NImyfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonuTWM2OD1zLkS0NlQh\|ryP	NV7LTWVJW0GQR1XS
COLO-741	NETPdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjVTYdKSzVyPUGuOFk4PzFizszN	NYK3XINQW0GQR1XS
LU-65	NUHBbIRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTFwNkKyOFkh\|ryP	MnzyV2FPT0WU
NCI-H1304	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFwNkW0PVgh\|ryP	NUHEV5VuW0GQR1XS
KARPAS-299	NIToPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHqTWM2OD1zLke5OFc6KM7:TR?=	MmjGV2FPT0WU
NCI-H358	NF[0bopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\vXWpKSzVyPUGuPVU2ODNizszN	M2S5ZnNCVkeHUh?=
OAW-28	M2XGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jzTWlEPTB;Mj6wOlkyQSEQvF2=	M4SxTHNCVkeHUh?=
C8166	NHjpUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnvcWsxUUN3ME2yMlY{Ozl{IN88US=>	NUTvUJJrW0GQR1XS
COLO-678	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJwOEO3Olgh\|ryP	MX7TRW5ITVJ?
SK-N-DZ	M4m0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwOE[zPFEh\|ryP	MVLTRW5ITVJ?
NCI-H82	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4X4cmlEPTB;Mj65NFM3QSEQvF2=	NI[2dVBUSU6JRWK=
JVM-2	NUPX[5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXRTWM2OD1\|LkCzNVg5KM7:TR?=	Mly5V2FPT0WU
SW1116	MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTNwMEW0NVEh\|ryP	NIrVNnRUSU6JRWK=
MDA-MB-453	NYixW2luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlq1TWM2OD1\|LkGwOFM6KM7:TR?=	NWLhfHQzW0GQR1XS
Calu-6	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTNwMUm5O{DPxE1?	M3PoPXNCVkeHUh?=
SHP-77	M{XWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYr3eJc6UUN3ME2zMlUzQCEQvF2=	NYLqcpg6W0GQR1XS
Capan-2	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3[4fmlEPTB;ND6zNlU5OSEQvF2=	NX[xN4VVW0GQR1XS
SW948	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjhTWM2OD12Lke0O\|c6KM7:TR?=	MnHMV2FPT0WU
HDLM-2	NV;USXlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTVwMEe3NlUh\|ryP	MknLV2FPT0WU
LAN-6	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HQXmlEPTB;Nj6yNVQ6PSEQvF2=	NWO2[HB1W0GQR1XS
LU-135	NUPEWlM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTqTWM2OD14LkSzNFc4KM7:TR?=	M2XSTXNCVkeHUh?=
T84	NXTE[W9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX[4W2N6UUN3ME22Mlk5PjRizszN	M4LtfXNCVkeHUh?=
CAPAN-1	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoGyTWM2OD15Lk[yNlM{KM7:TR?=	NEL1VlFUSU6JRWK=
SW1417	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrVfmhKSzVyPUeuPVE4OzFizszN	NIrmbplUSU6JRWK=
BALL-1	NF;h[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDZcI9KSzVyPUiuOVA1ODlizszN	NVzuWIw3W0GQR1XS
HT-29	M1HOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlryTWM2OD17LkC3OVk6KM7:TR?=	Mn\PV2FPT0WU
C3A	NGTPVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTjc\|lGUUN3ME25Mlg5Ozl2IN88US=>	Mn;EV2FPT0WU
NCI-H1993	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTFyLkWwPFEh\|ryP	MoDkV2FPT0WU
SK-MEL-1	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7Nd41KSzVyPUGxMlYzQDlizszN	M3TTOHNCVkeHUh?=
DU-145	M4XETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3La[mlEPTB;MUSuOVA2OiEQvF2=	M4HlcHNCVkeHUh?=
KP-N-YN	NHnFdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTF2LkWxNFMh\|ryP	Mn7XV2FPT0WU
CCRF-CEM	MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnLTWM2OD1zND63PFA6KM7:TR?=	NF;t[4hUSU6JRWK=
ZR-75-30	MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrONldKSzVyPUG2MlM{ODNizszN	M13JN3NCVkeHUh?=
A673	NYfzcFZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXtNFN1UUN3ME2yNE42PTB5IN88US=>	NGL0XIdUSU6JRWK=
K-562	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWK5[ll{UUN3ME2yPE41OTh\|IN88US=>	M3z3TXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

体内研究

BEZ235诱导肿瘤(69%)消退，而对体重增加没有统计学上显著的作用。总之，这些初步的体内功效研究结果表明，BEZ235单一口服给药时能够阻断疾病的发展，与其他抗癌药结合使用时能够增强疗效。^[1]

激酶实验： ^[2]	+ 展开体外蛋白激酶,PI3K,和mTOR实验: PI3Kα, β, δ蛋白都由与p110全长蛋白相接的p85 N端的iSH2域组成，只是PI3Kα没有最后的20个氨基酸。PI3Kγ由p110全长蛋白去掉前144个氨基酸产生而来。所有PI3K蛋白在羧基末端加组氨酸标签便于纯化，然后克隆到pBlue-Bac4.5 (用于α, β,和δ亚型) 或者pVL1393 (用于γ 亚型) 质粒中。转染BaculoGold WT基因组DNA的不同的载体按说明书推荐的方法生产各自重组体杆状病毒及重组蛋白。使用激酶发光检测试剂盒测定BEZ235 (NVP-BEZ235)作用于PI3K的活力。在384孔板上进行激酶实验。在每个孔中加入50 nl的测试项目（溶在90%DMSO中）和5ul的反应buffer,反应buffer包含10 μg/ml PI基质 (l-α-磷脂酰肌醇; 由Avanti Polar Lipids提供;预备在3%辛基葡萄糖苷中)，然后加入PI3K 蛋白(p110α, p110β, p110δ,和p110γ分别为10, 25, 10,和150 nM)。加入预备在反应buffer中的5 ul 1 µM 的ATP反应开始，反应进行60分钟 (测p110α, p110β, p110δ)或者120分钟(测p110γ)，随后加入10ul的荧光激酶buffer终止反应。数据用Synergy 2 阅读器阅读用于荧光测试。
细胞实验： ^[1]	+ 展开 Cell lines: HCT116, DLD-1, SW480 Concentrations: 0-1 μM Incubation Time: 48小时 Method: HCT116 (PIK3CA突变型; 激酶域在H1047R), DLD-1 (PIK3CA突变型；螺旋域在E545K), SW480 (PIK3CA 野生型)人类CRC细胞系，同基因型的DLD-1 PIK3CA突变和野生型细胞培养在含10%FBS和1×青霉素/链霉素的培养基中。细胞按不同的初始密度加入（HCT116: 3000个细胞/每孔, DLD-1: 5500个细胞/每孔, SW480: 4500个细胞/每孔, DLD-1 PIK3CA突变型: 7000个细胞/每孔, DLD-1 PIK3CA野生型: 9000个细胞/每孔)，用来计算不同的生长动力学。16个小时后，细胞加入浓度越来越高的BEZ235中进行温育，含有药物的培养基24小时更换一次。根据产品说明书，加入细胞16小时和药物处理48小时，使用单溶液细胞增殖检测试剂盒以比色法检测细胞活力。与没有用药物处理正在生长的细胞相比，药物处理的细胞的活力也逐渐趋于正常化。使用GraphPad Prism 5软件用4个参数的回归曲线计算IC50值。用于western blot 分析，细胞用0 nM 或者最高抑制剂量(500 nM) BEZ235处理 2, 6, 24, 或者48 小时。 (Only for Reference)
动物实验： ^[2]	+ 展开 Animal Models: 雌性Harlan无胸腺裸鼠 Formulation: NMP/聚乙二醇300(10/90,v/v) Dosages: 45 mg/kg Administration: 口服处理 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： NMP+polyethylene glycol 300 (10+90, v+v)	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dactolisib (BEZ235, NVP-BEZ235) SDF

分子量	469.55
化学式	C₃₀H₂₃N₅O
CAS号	915019-65-7
储存条件	3 years -20°C powder
储存条件	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03373903	Active not recruiting	Respiratory Tract Infections	Restorbio Inc.	November 15 2017	Phase 2
NCT03373903	Active not recruiting	Respiratory Tract Infections	Restorbio Inc.	November 15 2017	Phase 2
NCT01856101	Terminated	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01856101	Terminated	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01717898	Terminated	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
With difficulties in dissolving BEZ235, How can I improve its solubility?
回答：
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

选择性强的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
选择性强的PI3K抑制剂

TGX-221 : p110β-specific, IC50=5 nM.
活性最高的PI3K抑制剂

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA批准的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
最新的PI3K抑制剂

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

研究领域

产品类型

Dactolisib (BEZ235, NVP-BEZ235)

客户使用Selleck该产品发表文献180篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dactolisib (BEZ235, NVP-BEZ235) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

常见问题及建议解决方法

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品